We report a case of epidermal growth factor receptor (EGFR) 
Introduction

Carcinomatous meningitis is a clinically important neurological complication of systemic cancer, and often leads to a poor performance status. The prognosis for patients with carcinomatous meningitis is very poor, with a median survival of only 4 weeks (1).
Gefitinib (Iressa (4, 5) . Several case reports have indicated that gefitinib may also be effective against carcinomatous meningitis (6) (7) (8) .
TM ; AstraZeneca, Wilmington, DE) is an oral tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), and large clinical trials have demonstrated its anticancer activity in patients with non-small cell lung cancer (NSCLC) (2, 3). It has also been reported that mutations of the EGFR gene can predict prolonged survival after gefitinib treatment in patients with NSCLC
We report a NSCLC patient with carcinomatous meningitis, in whom an EGFR mutation was detected that brought about a good clinical response to gefitinib treatment. To the best of our knowledge, this is the first report demonstrating evidence of an EGFR mutation in cerebrospinal fluid (CSF) . Furthermore, this case suggests that an EGFR mutation can be detected in a small amount of CSF, despite negative cytology. (Fig. 1B) , suggesting lung adenocarcinoma. Aspiration pneumonia due to his deteriorated consciousness was also recognized (Fig. 1B) . Abnormal F18-fluorodeoxyglucose uptake (SUV 6.7) into the tumor was seen on positron emission tomography scanning, and there was no other abnormal uptake into the lesion (Fig. 1C) (Fig. 3) . (Fig. 4) . The clinical effectiveness to gefitinib treatment was a partial response. (10) . In the present case, the EGFR mutation was identified in the first CSF, despite negative CSF cytology. Among lung cancers, the most frequently involved histological types are adenocarcinoma and small cell lung cancer (1) , and EGFR mutations are seen in the majority of adenocarcinomas (4 (6) (7) (8) as well as brain metastasis (13) (14) (15) 
F i g u r e 1 . ( A) He a d CT s h o ws e n h a n c e me n t o f t h e b r a i n s u r f a c e , i n d i c a t i n g c a r c i n o ma t o u s me ni n g i t i s ( a r r o w) . ( B ) Ch e s t CT s h o ws p r i ma r y l u n g c a n c e r i n t h e r i g h t u p p e r l o b e ( a r r o w) a n d a s p ir a t i o n p n e u mo n i a i n t h e l e f t S 6 a r e a ( a r r o wh e a d ) . ( C) T h e r e i s n o a b n o r ma l u p t a k e o f F 1 8 -f l u o r od e o x y g l u c o s e e x c e p t f o r t h e p r i ma r y l e s i o n ( a r r o w) o n p o s i t r o n e mi s s i o n t o mo g r a p h y .
F i g u r e 3 . S e q u e n c i n g o f E GF R f r o m t h e p a t i e n t ' s CS F s a mp l e c o n f i r ms t h e L 8 5 8 R mu t a t i o n .
F i g u r e 4 . T h e p r i ma r y l e s i o n r e g r e s s e d s i g n i f i c a n t l y 2 mo n t h s a f t e r i n i t i a t i n g g e f i t i n i b t h e r a p y .
The other EGFR mutations were not detected (data not shown). Since his Eastern Cooperative Oncology Group performance status was 4, conventional intravenous chemotherapy was considered to be risky. On the other hand, the presence of EGFR mutation was evident. Although gefitinib therapy could not be allowed for the first therapy, he was treated with gefitinib (250 mg/day) with his family's agreement. After 2 weeks, his consciousness level had improved significantly. After 2 months, his consciousness became alert, and the primary lesion was markedly regressed
Discussion
The present case suggests that gefitinib may be a powerful therapeutic option for carcinomatous meningitis in NSCLC patients. To the best of our knowledge, this is the first report to show a positive association between the evidence of an EGFR mutation in the CSF and a great benefit of gefitinib treatment for carcinomatous meningitis. Carcinomatous meningitis is often found in patients with metastatic malignancies, and can also be the initial manifestation of an underlying malignancy (9). Although the diagnosis can generally be made by cytologic examination of the CSF, it has been reported that the initial cytologic examination is only diagnostic in approximately 50% of the cases
